Claims
- 1. A method of inhibiting both angiotensin converting enzyme and neutral endopeptidase for treatment of a disease which comprises administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I)
- 2. The method according to claim 1 wherein the disease is selected from the group consisting of non-diabetic nephropathy, diabetic nephropathy, insulin resistance, diabetic neuropathy, diabetic retinopathy, myocardial infarction, cataracts, diabetic cardiomyopathy, atherosclerosis and endothelial dysfunction.
- 3. The method according to claim 2 wherein the disease is non-diabetic nephropathy.
- 4. The method according to claim 2 wherein the disease is diabetic nephropathy.
- 5. The method according to claim 2 wherein the disease is insulin resistance.
- 6. The method according to claim 2 wherein the disease is diabetic neuropathy.
- 7. The method according to claim 2 wherein the disease is diabetic retinopathy.
- 8. The method according to claim 2 wherein the disease is myocardial infarction.
- 9. The method according to claim 2 wherein the disease is cataracts.
- 10. The method according to claim 2 wherein the disease is diabetic cardiomyopathy.
- 11. The method according to claim 2 wherein the disease is atherosclerosis.
- 12. The method according to claim 2 wherein the disease is endothelial dysfunction.
- 13. The method according to claim 1, wherein the compound is the compound of formula (II)
- 14. The method according to claim 13, wherein R1 is acetyl.
- 15. The method according to claim 13, wherein R1 is hydrogen.
- 16. The method according to claim 13, wherein B1 and B2 are hydrogen.
- 17. The method according to claim 13, wherein X is —CH2.
- 18. The method according to claim 1, wherein the compound is the compound of formula (II-A)
- 19. The method according to claim 18, wherein the compound has the formula (II-B)
- 20. The method according to claim 18, wherein the compound has the formula (II-C)
- 21. The method according to claim 1, wherein the compound is the compound of formula (III)
- 22. The method according to claim 21, wherein R1 is acetyl.
- 23. The method according to claim 21, wherein R1 is hydrogen.
- 24. The method according to claim 21, wherein B1 and B2 are hydrogen.
- 25. The method according to claim 21, wherein X is —CH2.
- 26. The method according to claim 1, wherein the compound is the compound of formula (III-A)
- 27. The method according to claim 26, wherein the compound has the formula (III-B)
- 28. The method according to claim 26, wherein the compound has the formula (III-C)
- 29. A method for inhibition of both angiotensin converting enzyme and neutral endopeptidase which comprises administering to a patient in need of said inhibition an effective inhibitory amount of a compound of formula (I)
- 30. A method for the preparation of a pharmaceutical composition having both angiotensin converting enzyme and neutral endopeptidase inhibitory activity for treatment of a disease comprising mixing a pharmaceutically acceptable carrier, optionally one or more pharmaceutically acceptable excipients, and a therapeutically effective amount of a compound of formula (I)
Priority Claims (1)
Number |
Date |
Country |
Kind |
10229180.2-41 |
Jun 2002 |
DE |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority of German Patent Application No. 10229180.2-41, filed Jun. 28, 2002, and the benefit of U.S. Provisional Application No. 60/423,590, filed Nov. 4, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60423590 |
Nov 2002 |
US |